ランキング価格はじめての方へ
  1. 米国企業
  2. Travere Therapeutics, Inc.

Travere Therapeutics, Inc.TVTX

時価総額
$11.5億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2012年
2月29日		2012年
12月31日		2013年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Depreciation and amortization-125,240341,233131618192025273339
Share based compensation-18-262927202124313944
Net Change in Fair Value of Contingent Consideration--------342215-
Loss on extinguishment of debt----4---17----8-
Payments from change in fair value of contingent consideration---14181912--12-14-9-
Inventory Write-down---------223
Loss on extinguishment of debt----4---17----8-
Amortization of debt discount and issuance costs---111310101122
Inventory Write-down---------223
Amortization of (discounts) premiums on investments-------1-1-2-7
Amortization of debt discount and issuance costs---111310101122
Other------100-1-5-14
Acquired IPR&D expense--------97---
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Other------100-1-5-14
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Net income from discontinued operations-----------265
Net cash used in operating activities-49-2,736,739-17,589,168--7-25-58-43-15-186-280
Net loss from continuing operations-0.14-----------376
Depreciation and amortization-125,240341,233131618192025273339
Share based compensation-18-262927202124313944
Net Change in Fair Value of Contingent Consideration--------342215-
Loss on extinguishment of debt----4---17----8-
Payments from change in fair value of contingent consideration---14181912--12-14-9-
Inventory Write-down---------223
Loss on extinguishment of debt----4---17----8-
Amortization of debt discount and issuance costs---111310101122
Inventory Write-down---------223
Amortization of (discounts) premiums on investments-------1-1-2-7
Amortization of debt discount and issuance costs---111310101122
Other------100-1-5-14
Acquired IPR&D expense--------97---
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Other------100-1-5-14
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Net cash used in operating activities - continuing operations----1-2-------325
Net cash provided by operating activities - discontinued operations-----------45
Net cash used in operating activities-49-2,736,739-17,589,168--7-25-58-43-15-186-280
Proceeds from the sale/maturity of marketable debt securities----------382335
Purchase of marketable debt securities--4199184102331224215547385444
Purchase of fixed assets--24,774144,679011107501
Purchase of intangible assets--1,168,093571013191518192842
Purchase of IPR&D, net of cash acquired---331---95---
Other----------1-
Other----------1-
Net cash used in investing activities - continuing operations----8110-------152
Net cash provided by (used in) investing activities-2-5,406,425--46-20320-61-138-3356
Net cash provided by investing activities - discontinued operations-----------207
Net cash provided by (used in) investing activities-2-5,406,425--46-20320-61-138-3356
Payment of guaranteed minimum royalty-------22222
Payment of business combination-related contingent consideration-----4103862-
Proceeds from Convertible Debt----------316-
Proceeds from Convertible Debt----------316-
Payment of debt issuance costs----------10-
Payment of debt issuance costs----------10-
Repurchase of 2025 convertible senior notes including premium----------211-
Repurchase of 2025 convertible senior notes including premium----------211-
Underwritten Equity Offering--------109---
At-The-Market Offering--------23---
At-The-Market Offering--------23---
Proceeds from Issuance of Common Stock-435149-------191
Proceeds from Stock Options Exercised---74811241353
Proceeds from Issuance of Warrants---4645----25
Proceeds from Stock Plans----------33
Proceeds from Stock Options Exercised---74811241353
Underwritten Equity Offering---------189--
At-The-Market Offering---------3620-
At-The-Market Offering---------3620-
Proceeds from Stock Plans----------33
Net cash provided by financing activities-534101-65232-2128232118219
Underwritten Equity Offering---------189--
At-The-Market Offering---------3620-
At-The-Market Offering---------3620-
Net cash provided by financing activities - continuing operations-----------220
Net cash used in financing activities - discontinued operations------------1
Net cash provided by financing activities-534101-65232-2128232118219
Effect of exchange rate changes on cash--------0-12-32
Net (decrease) increase in cash and cash equivalents--------402281-104-4
Operating Lease, Payments----------66
Cash paid for interest------2877109
Cash (paid) refunded for income taxes---------3-1611
Accrued capital expenditures--------2---
Accrued Royalty In Excess Of Minimum Payable To Sellers-------1618191616
Accrued Royalty In Excess Of Minimum Payable To Sellers-------1618191616